Work overview

Section 05 of 05

Conclusions

Recommendations for selection, treatment, and follow-up in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors: a Delphi consensus from the Galician Multidisciplinary Group on Neuroendocrine and Endocrine Tumors (GGNET)

Nieves Martinez-Lago, José Manuel Cabezas Agricola, Urbano Anido Herranz, Zulema Nogareda Seoane, Antía Cousillas Castiñeiras, Rafael Varela Ponte, Pablo Fernández Catalina, Estephany Abou Jokh Casas, José María de Matías Leralta, and Virginia Pubul Nuñez · 2026

Contents

Section 05 of 05

  1. 01Introduction
  2. 02Material and methods
  3. 03Results
  4. 04Discussion
  5. 05Conclusions
Text size
Work overview

Section 5 of 5

Conclusions

Nieves Martinez-Lago, José Manuel Cabezas Agricola, Urbano Anido Herranz, Zulema Nogareda Seoane, Antía Cousillas Castiñeiras, Rafael Varela Ponte, Pablo Fernández Catalina, Estephany Abou Jokh Casas, José María de Matías Leralta, and Virginia Pubul Nuñez · about 1 minutes

Original source ↗

This Delphi consensus by the GGNET provides pragmatic, multidisciplinary, expert-based recommendations for the selection, administration, and follow-up of patients undergoing PRRT. The panel emphasizes the central role of SSTR-PET imaging in establishing eligibility, the complementary (non-exclusionary) value of [18F]-FDG-PET in selected scenarios, and the importance of multidisciplinary evaluation to optimize the sequencing of systemic therapies and overall patient outcomes.

The proposed algorithm (Fig. 1) offers a structured and pragmatic framework to harmonize practice across centers, supporting routine clinical decision-making by integrating evidence from randomized trials, real-world cohorts, and expert opinion. Rather than redefining indications, this work aims to reduce variability in care and support decision-making in day-to-day clinical practice.

Fig. 1: Selection, treatment, response evaluation and follow-up of patients for PRRT

Fig. 1: Selection, treatment, response evaluation and follow-up of patients for PRRT

Despite robust evidence supporting PRRT in GEP-NETs, uncertainties persist regarding its role in non-GEP primaries, the utility of circulating and functional biomarkers, and the optimal operational use of PRRT within standard treatment pathways, including patient selection and follow-up strategies. Continued prospective research is warranted to refine patient selection, optimize treatment schedules, and better define the long-term impact of PRRT.